Biolase Inc.
| NASDAQ: BIOL |
| Healthcare / Medical Devices & Instruments / USA |
| 4.53 | +0.3100 | +7.35% | Vol 26.67K | 1Y Perf 474.23% |
| Jun 24th, 2022 15:58 DELAYED |
| BID | 4.50 | ASK | 4.60 | ||
| Open | 4.27 | Previous Close | 4.22 | ||
| Pre-Market | - | After-Market | 4.58 | ||
| - - | 0.05 1.10% |
| Target Price | 17.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 286.31 | Finscreener Ranking | ★★★+ 51.37 | |
| Insiders Trans % 3/6/12 mo. | -/-/33 | Value Ranking | ★★ 46.87 | |
| Insiders Value % 3/6/12 mo. | -/-/85 | Growth Ranking | ★ 36.82 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/81 | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.09 | Earnings Rating | Buy | |
| Market Cap | 27.97M | Earnings Date | 11th Aug 2022 | |
| Alpha | -0.03 | Standard Deviation | 0.32 | |
| Beta | 1.64 |
Today's Price Range 4.234.64 | 52W Range 3.3023.49 | 5 Year PE Ratio Range -1.10-1.20 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.66% | ||
| 1 Month | -5.43% | ||
| 3 Months | 1 198.74% | ||
| 6 Months | 1 032.50% | ||
| 1 Year | 474.23% | ||
| 3 Years | 210.27% | ||
| 5 Years | -3.62% | ||
| 10 Years | -55.15% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -92.63 | |||
ROE last 12 Months | -52.75 | |||
ROA (5Y Avg) | -24.19 | |||
ROA last 12 Months | -25.08 | |||
ROC (5Y Avg) | -66.32 | |||
ROC last 12 Months | -29.49 | |||
Return on invested Capital Q | -12.28 | |||
Return on invested Capital Y | -11.38 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 4.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.10 | ||||
| 1.37 | ||||
| 0.68 | ||||
| - | ||||
| -1.50 | ||||
| -2.99 | ||||
| 1.59 | ||||
| 3.34 | ||||
| 22.41M | ||||
| Forward PE | -43.29 | |||
| PEG | -0.18 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.00 | ||||
| 3.30 | ||||
| 0.43 | ||||
| 0.77 | ||||
| -5.70 | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 44.90 | ||||
| -28.90 | ||||
| -27.90 | ||||
| -49.30 | ||||
| -34.03 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 41.24M | ||||
| 6.68 | ||||
| -5.14 | ||||
| -8.50 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | - | -0.81 | - |
| Q04 2021 | -0.75 | -0.75 | 0.00 |
| Q03 2021 | -0.75 | -0.50 | 33.33 |
| Q02 2021 | -1.00 | -0.50 | 50.00 |
| Q01 2021 | -1.25 | -1.50 | -20.00 |
| Q04 2020 | -1.00 | -1.75 | -75.00 |
| Q03 2020 | -0.06 | -0.21 | -250.00 |
| Q02 2020 | -0.19 | -0.12 | 36.84 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2019 QR | -0.21 | 0.00 | - |
| 3/2022 QR | -0.03 | 70.00 | Positive |
| 12/2022 FY | -0.10 | - | - |
| 12/2022 FY | -0.10 | 0.00 | - |
| Next Report Date | 11th Aug 2022 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 26.67K |
| Shares Outstanding | 6.17K |
| Shares Float | 6.09M |
| Trades Count | 454 |
| Dollar Volume | 119.66K |
| Avg. Volume | 185.57K |
| Avg. Weekly Volume | 25.88K |
| Avg. Monthly Volume | 25.87K |
| Avg. Quarterly Volume | 504.96K |
Biolase Inc. (NASDAQ: BIOL) stock closed at 4.53 per share at the end of the most recent trading day (a 7.35% change compared to the prior day closing price) with a volume of 26.67K shares and market capitalization of 27.97M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.
The one-year performance of Biolase Inc. stock is 474.23%, while year-to-date (YTD) performance is 1061.54%. BIOL stock has a five-year performance of -3.62%. Its 52-week range is between 3.3 and 23.485, which gives BIOL stock a 52-week price range ratio of 6.09%
Biolase Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 1.37, a price-to-sale (PS) ratio of 0.68, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.08%, a ROC of -29.49% and a ROE of -52.75%. The company’s profit margin is -34.03%, its EBITDA margin is -27.90%, and its revenue ttm is $41.24 Million , which makes it $6.68 revenue per share.
Of the last four earnings reports from Biolase Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biolase Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1), with a target price of $17.5, which is +286.31% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biolase Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 34.25, ATR14 : 0.34, CCI20 : -35.57, Chaikin Money Flow : -0.28, MACD : 0.16, Money Flow Index : 46.27, ROC : -3.00, RSI : 56.14, STOCH (14,3) : 60.25, STOCH RSI : 0.81, UO : 43.64, Williams %R : -39.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biolase Inc. in the last 12-months were: John R. Beaver (Buy at a value of $52 850), Jonathan T. Lord (Sold 11 038 shares of value $4 194 )
Biolase Inc.
Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
CEO: John R. Beaver
Telephone: +1 949 361-1200
Address: 4 Cromwell, Irvine 92618, CA, US
Number of employees: 157
TipRanks News for BIOL
Tue, 25 Jan 2022 13:35 GMT Analysts Are Bullish on These Healthcare Stocks: Biolase (BIOL), Supernus Pharmaceuticals (SUPN)
- TipRanks. All rights reserved.
